Oxycodone and Hydrocodone Are Essentially Equivalent for Acute Pain
For adult patients with moderate to severe acute pain, oxycodone and hydrocodone demonstrate comparable analgesic efficacy with no clinically meaningful differences in pain relief, making either agent an acceptable choice when opioids are indicated. The selection between these two agents should be based on practical considerations including formulation availability, cost, and individual patient factors rather than expected differences in pain control 1.
Evidence Base for Equivalence
The most robust comparative data comes from multiple randomized controlled trials directly comparing these agents:
Emergency department acute pain studies consistently show no clinically significant differences. A 2015 RCT of 220 patients with acute musculoskeletal extremity pain found mean pain reduction of 4.4 NRS units with oxycodone/acetaminophen versus 4.0 units with hydrocodone/acetaminophen—a difference of only 0.4 units, well below the clinically meaningful threshold 2.
Fracture pain management demonstrated similar findings: a 2005 double-blind RCT in ED patients with fractures showed both agents provided significant pain relief at 30 and 60 minutes with no difference between groups (mean difference -0.6 at 30 minutes, -0.5 at 60 minutes) 3.
Low back pain treatment showed equivalent efficacy in a multicenter trial comparing hydrocodone 7.5mg/ibuprofen with oxycodone 5mg/acetaminophen over 8 days, with no significant differences in pain relief scores, doses taken, or functional outcomes 4.
The 2013 Critical Care emergency medicine guideline explicitly states: "We are unable to comment on the superiority/inferiority of either of these drugs in treating acute pain" based on systematic review of available evidence 5.
Equianalgesic Dosing
According to the 2025 NCCN Cancer Pain Guidelines, the oral equianalgesic doses are 6:
- Oxycodone: 15-20 mg (duration 3-5 hours)
- Hydrocodone: 30-45 mg (duration 3-5 hours)
This approximately 2:1 ratio (hydrocodone to oxycodone) should guide dose conversions. The 2012 ACEP Clinical Policy confirms that equianalgesic doses of opioids are equally efficacious in relieving pain, regardless of DEA schedule classification 1.
Recent Surgical Data Favoring Hydrocodone
Important caveat: A 2026 cohort study of 663 CYP2D6 normal metabolizers undergoing joint arthroplasty found hydrocodone associated with significantly lower composite pain scores (9.0 vs 9.3, p=0.001) and substantially lower cumulative opioid consumption (93.5 vs 154.5 MME, p<0.001) compared to oxycodone 7. This suggests hydrocodone may be preferable in the postoperative orthopedic setting, though findings were consistent for knee but not hip arthroplasty.
Side Effect Profiles
Adverse effects are generally comparable between the two agents:
The 2005 fracture study found higher constipation rates with hydrocodone (21% vs 0%, p<0.05), though other side effects (nausea, vomiting, drowsiness) were similar 3.
The 2015 extremity pain study reported no significant differences in adverse event rates (62.7% vs 62.5%) 2.
A 2005 dental pain study comparing oxycodone/ibuprofen with hydrocodone/acetaminophen found lower nausea and vomiting rates with oxycodone/ibuprofen (6.5% and 3.2%) versus hydrocodone/acetaminophen (though not statistically significant for vomiting) 8.
Practical Prescribing Considerations
When Opioids Are Indicated
The 2020 ACEP Clinical Policy emphasizes that opioid prescribing should be reserved for patients where alternative treatments are inadequate or contraindicated 9. The FDA label for oxycodone specifies use only when "alternative treatment options have not been tolerated or have not provided adequate analgesia" 10.
Dosing Recommendations
For opioid-naïve adults 10:
- Initial dose: 5-15 mg oxycodone (or equivalent hydrocodone 10-30 mg) every 4-6 hours as needed
- Start at the lower end for frail or elderly patients
- Titrate based on individual response
- Prescribe for ≤5-7 days for acute pain
- Use the lowest practical dose
- Avoid routine prescribing for chronic pain exacerbations
Critical Safety Points
Renal impairment: Both oxycodone and hydrocodone should be used with caution in patients with fluctuating renal function due to accumulation of renally cleared metabolites 6. Monitor for neurologic adverse effects.
Multimodal analgesia: The 2017 JAMA trial demonstrated that ibuprofen plus acetaminophen provided pain relief equivalent to opioid combinations for acute extremity pain, with mean NRS reduction of 4.3 units 11. The 2020 ACP/AAFP guideline recommends NSAIDs as first-line for musculoskeletal pain 12.
Never prescribe as monotherapy: Opioids should always be part of a multimodal approach including non-opioid analgesics 13.
Formulation Limitations
Hydrocodone availability: Immediate-release hydrocodone is only commercially available combined with acetaminophen or ibuprofen in the United States 6. The FDA limits acetaminophen to ≤325 mg per dosage unit. This constrains dosing flexibility compared to oxycodone, which is available as a single-entity immediate-release formulation.
Clinical Decision Algorithm
First: Attempt non-opioid multimodal analgesia (NSAIDs + acetaminophen)
If opioids indicated: Choose based on:
Prescribe: 5-15 mg oxycodone OR 10-30 mg hydrocodone q4-6h PRN for ≤5-7 days
Always provide: Naloxone, storage/disposal instructions, laxative prophylaxis
The bottom line: These agents are interchangeable for acute pain when dosed appropriately, with selection driven by practical rather than efficacy considerations.